We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

1 hedge funds and large institutions have $10.2K invested in Apellis Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 279 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 323 → 1 (-322)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $5.56B → $10.2K (-$5.56B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 279

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

109.78% less ownership

Funds ownership: 109.78% → 0% (-110%)

Holders
1
Holders Change
-322
Holders Change %
-99.69%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
279
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$545M
2
ACA
Avoro Capital Advisors
New York
-$492M
3
Morgan Stanley
Morgan Stanley
New York
-$404M
4
State Street
State Street
Massachusetts
-$275M
5
UBS Group
UBS Group
Switzerland
-$250M
Name Holding Trade Value Shares
Change 		Change in
Stake
TH
151
Transmarket Holdings
Illinois
– -$949K -23,585 Closed
OPERF
152
Oregon Public Employees Retirement Fund
Oregon
– -$941K -23,400 Closed
EFM
153
E Fund Management
China
– -$913K -22,686 Closed
CUAMC
154
China Universal Asset Management Company
China
– -$913K -22,684 Closed
Fifth Third Bancorp
155
Fifth Third Bancorp
Ohio
– -$889K -22,102 Closed
GI
156
GAMCO Investors
Connecticut
– -$845K -21,000 Closed
MSRPS
157
Maryland State Retirement & Pension System
Maryland
– -$837K -20,816 Closed
Rockefeller Capital Management
158
Rockefeller Capital Management
New York
– -$830K -20,634 Closed
JC
159
JBF Capital
Colorado
– -$826K -20,532 Closed
SC
160
SummitTX Capital
Texas
– -$819K -20,351 Closed
CHAM
161
Clear Harbor Asset Management
Connecticut
– -$805K -20,000 Closed
Victory Capital Management
162
Victory Capital Management
Texas
– -$797K -19,817 Closed
Canada Pension Plan Investment Board
163
Canada Pension Plan Investment Board
Ontario, Canada
– -$789K -19,600 Closed
Vanguard Investments Australia
164
Vanguard Investments Australia
Australia
– -$774K -19,240 Closed
EGM
165
Engineers Gate Manager
New York
– -$772K -19,197 Closed
X
166
Xponance
Pennsylvania
– -$746K -18,550 Closed
New York State Teachers Retirement System (NYSTRS)
167
New York State Teachers Retirement System (NYSTRS)
New York
– -$736K -18,299 Closed
DWAM
168
Duncan Williams Asset Management
Tennessee
– -$684K -17,005 Closed
KK
169
KLP Kapitalforvaltning
Norway
– -$652K -16,200 Closed
STA
170
Summit Trail Advisors
New York
– -$645K -16,023 Closed
GS
171
GTS Securities
New York
– -$628K -15,604 Closed
VA
172
Vident Advisory
Georgia
– -$607K -15,079 Closed
BC
173
Birchview Capital
Vermont
– -$563K -14,000 Closed
DO
174
denkapparat Operations
Germany
– -$536K -13,334 Closed
DWM
175
Dynasty Wealth Management
Florida
– -$536K -13,321 Closed
5 6
7
8 9

APLS Hedge Fund Activity: Q2 2026 in Review

1 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2026, worth a combined $10.2K — down 100% from $5.56B a quarter earlier.

Sellers outnumbered buyers: 279 funds closed out of APLS and 0 opened new positions — a net loss of 279 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $545M sold.

  • 1 institutional investor held Apellis Pharmaceuticals (APLS) as of Q2 2026, down from 323 in Q1 2026.
  • Funds reported $10.2K of Apellis Pharmaceuticals stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Apellis Pharmaceuticals positions in Q2 2026 and 279 closed out, a net change of -279 holders.
  • The largest Apellis Pharmaceuticals seller in Q2 2026 was BlackRock, an estimated $545M sold.

Based on aggregated 13F filings for Q2 2026.